Phosphate Prodrugs: An Approach to Improve the Bioavailability of Clinically Approved Drugs


Cite item

Full Text

Abstract

The phosphate prodrug approach has emerged as a viable option for increasing the bioavailability of a drug candidate with low hydrophilicity and poor cell membrane permeability. When a phosphoric acid moiety is attached to the parent drug, it results in a several-fold elevation in aqueous solubility which helps to achieve desired bioavailability of the pharmaceutically active parental molecule. The neutral phosphate prodrugs have rapid diffusion ability through the plasma membrane as compared to their charged counterpart. The presence of phosphate mono ester breaking alkaline phosphatase (ALP) enzyme throughout the whole human body, is the main consideration behind the development of phosphate prodrug strategy. The popularity of this phosphate prodrug strategy is increasing nowadays due to the fulfillment of different desired pharmacokinetic characteristics required to get pharmaceutical and therapeutic responses without showing any serious adverse drug reactions (ADR). This review article mainly focuses on various phosphate prodrugs synthesized within the last decade to get an improved pharmacological response of the parent moiety along with various preclinical and clinical challenges associated with this approach. Emphasis is also given to the chemical mechanism to release the parent moiety from the prodrug.

About the authors

Tanmoy Tantra

Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab

Email: info@benthamscience.net

Yogesh Singh

Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences,, Central University of Punjab, Bathinda

Email: info@benthamscience.net

Rohan Patekar

Department of Pharmaceutical Sciences and Natural Products, School of Health Science, Central University of Punjab

Email: info@benthamscience.net

Swanand Kulkarni

Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab

Email: info@benthamscience.net

Pradeep Kumar

Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab

Email: info@benthamscience.net

Suresh Thareja

Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences,, Central University of Punjab

Author for correspondence.
Email: info@benthamscience.net

References

  1. Singh, Y.; Saklani, S.; Tantra, T.; Thareja, S. Amino acid derived prodrugs: An approach to improve the bioavailability of clinically approved drugs. Curr. Top. Med. Chem., 2021, 21(24), 2170-2183. doi: 10.2174/1568026621666210602154438 PMID: 34080965
  2. Abet, V.; Filace, F.; Recio, J.; Alvarez-Builla, J.; Burgos, C. Prodrug approach: An overview of recent cases. Eur. J. Med. Chem., 2017, 127, 810-827. doi: 10.1016/j.ejmech.2016.10.061 PMID: 27823878
  3. Singh, Y.; Palombo, M.; Sinko, P. Recent trends in targeted anticancer prodrug and conjugate design. Curr. Med. Chem., 2008, 15(18), 1802-1826. doi: 10.2174/092986708785132997 PMID: 18691040
  4. Schultz, C. Prodrugs of biologically active phosphate esters. Bioorg. Med. Chem., 2003, 11(6), 885-898. doi: 10.1016/S0968-0896(02)00552-7 PMID: 12614874
  5. Krise, J.P.; Stella, V.J. Prodrugs of phosphates, phosphonates, and phosphinates. Adv. Drug Deliv. Rev., 1996, 19(2), 287-310. doi: 10.1016/0169-409X(95)00111-J
  6. Müller, C.E. Prodrug approaches for enhancing the bioavailability of drugs with low solubility. Chem. Biodivers., 2009, 6(11), 2071-2083. doi: 10.1002/cbdv.200900114 PMID: 19937841
  7. Redasani, V.K.; Bari, S.B. Prodrug Design: Perspectives, Approaches and Applications in Medicinal Chemistry; Academic Press: Massachusetts, USA, 2015.
  8. Dal Corso, A.; Pignataro, L.; Belvisi, L.; Gennari, C. Innovative linker strategies for tumor-targeted drug conjugates. Chemistry, 2019, 25(65), 14740-14757. doi: 10.1002/chem.201903127 PMID: 31418970
  9. Kumpulainen, H.; Järvinen, T.; Mannila, A.; Leppänen, J.; Nevalainen, T.; Mäntylä, A.; Vepsäläinen, J.; Rautio, J. Synthesis, in vitro and in vivo characterization of novel ethyl dioxy phosphate prodrug of propofol. Eur. J. Pharm. Sci., 2008, 34(2-3), 110-117. doi: 10.1016/j.ejps.2008.02.121 PMID: 18403185
  10. Vale, N.; Ferreira, A.; Matos, J.; Fresco, P.; Gouveia, M. Amino acids in the development of prodrugs. Molecules, 2018, 23(9), 2318. doi: 10.3390/molecules23092318 PMID: 30208629
  11. N’Da, D. Prodrug strategies for enhancing the percutaneous absorption of drugs. Molecules, 2014, 19(12), 20780-20807. doi: 10.3390/molecules191220780 PMID: 25514222
  12. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Järvinen, T.; Savolainen, J. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov., 2008, 7(3), 255-270. doi: 10.1038/nrd2468 PMID: 18219308
  13. Shirke, S.; Shewale, S.; Satpute, M. Prodrug design: an overview. Int. J. Pharm. Chem. Biol. Sci., 2015, 5(1), 232-241.
  14. Hajnal, K.; Gabriel, H.; Aura, R.; Erzsébet, V.; Blanka, S.S. Prodrug strategy in drug development. Acta Med. Marisiensis, 2016, 62(3), 356-362. doi: 10.1515/amma-2016-0032
  15. Huttunen, K.M.; Raunio, H.; Rautio, J. Prodrugs--from serendipity to rational design. Pharmacol. Rev., 2011, 63(3), 750-771. doi: 10.1124/pr.110.003459 PMID: 21737530
  16. DeGoey, D.A.; Grampovnik, D.J.; Flosi, W.J.; Marsh, K.C.; Wang, X.C.; Klein, L.L.; McDaniel, K.F.; Liu, Y.; Long, M.A.; Kati, W.M.; Molla, A.; Kempf, D.J. Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir. J. Med. Chem., 2009, 52(9), 2964-2970. doi: 10.1021/jm900080g PMID: 19348416
  17. A M Subbaiah, M.; Mandlekar, S.; Desikan, S.; Ramar, T.; Subramani, L.; Annadurai, M.; Desai, S.D.; Sinha, S.; Jenkins, S.M.; Krystal, M.R.; Subramanian, M.; Sridhar, S.; Padmanabhan, S.; Bhutani, P.; Arla, R.; Singh, S.; Sinha, J.; Thakur, M.; Kadow, J.F.; Mean-well, N.A.M; Mandlekar, S.; Desikan, S.; Ramar, T.; Subramani, L.; Annadurai, M.; Desai, S.D.; Sinha, S.; Jenkins, S.M.; Krystal, M.R. Design, synthesis, and pharmacokinetic evaluation of phosphate and amino acid ester prodrugs for improving the oral bioavailability of the HIV-1 protease inhibitor atazanavir. J. Med. Chem., 2019, 62(7), 3553-3574. doi: 10.1021/acs.jmedchem.9b00002 PMID: 30938524
  18. Fechner, J.; Schwilden, H.; Schüttler, J. Pharmacokinetics and pharmacodynamics of GPI 15715 or fospropofol (Aquavan injection)—a water-soluble propofol prodrug; Modern Anesthetics, 2008, pp. 253-266. doi: 10.1007/978-3-540-74806-9_12
  19. Stella, V.J.; Nti-Addae, K.W. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev., 2007, 59(7), 677-694. doi: 10.1016/j.addr.2007.05.013 PMID: 17628203
  20. Sauer, R.; Maurinsh, J.; Reith, U.; Fülle, F.; Klotz, K.N.; Müller, C.E. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J. Med. Chem., 2000, 43(3), 440-448. doi: 10.1021/jm9911480 PMID: 10669571
  21. Takeda, E.; Taketani, Y.; Sawada, N.; Sato, T.; Yamamoto, H. The regulation and function of phosphate in the human body. Biofactors, 2004, 21(1-4), 345-355. doi: 10.1002/biof.552210167 PMID: 15630224
  22. Penido, M.G.M.G.; Alon, U.S. Phosphate homeostasis and its role in bone health. Pediatr. Nephrol., 2012, 27(11), 2039-2048. doi: 10.1007/s00467-012-2175-z PMID: 22552885
  23. Wagner, C.A.; Hernando, N.; Forster, I.C.; Biber, J. The SLC34 family of sodium-dependent phosphate transporters. Pflugers Arch., 2014, 466(1), 139-153. doi: 10.1007/s00424-013-1418-6 PMID: 24352629
  24. Tsai, J.Y.; Chu, C.H.; Lin, M.G.; Chou, Y.H.; Hong, R.Y.; Yen, C.Y.; Hsiao, C.D.; Sun, Y.J. Structure of the sodium-dependent phosphate transporter reveals insights into human solute carrier SLC20. Sci. Adv., 2020, 6(32), eabb4024. doi: 10.1126/sciadv.abb4024 PMID: 32821837
  25. Heimbach, T.; Oh, D-M.; Li, L.Y.; Forsberg, M.; Savolainen, J.; Leppänen, J.; Matsunaga, Y.; Flynn, G.; Fleisher, D. Absorption rate limit considerations for oral phosphate prodrugs. Pharm. Res., 2003, 20(6), 848-856. doi: 10.1023/A:1023827017224 PMID: 12817887
  26. Le-Vinh, B.; Akkuş-Dağdeviren, Z.B.; Le, N.M.N.; Nazir, I.; Bernkop-Schnürch, A. Alkaline Phosphatase: A reliable endogenous partner for drug delivery and diagnostics. Adv. Ther. (Weinh.), 2022, 5(2), 2100219. doi: 10.1002/adtp.202100219
  27. Ramalingam, M.; Kim, H.; Lee, Y.; Lee, Y.I. Phytochemical and pharmacological role of liquiritigenin and isoliquiritigenin from Radix glycyrrhizae in human health and disease models. Front. Aging Neurosci., 2018, 10, 348. doi: 10.3389/fnagi.2018.00348 PMID: 30443212
  28. Peng, F.; Du, Q.; Peng, C.; Wang, N.; Tang, H.; Xie, X.; Shen, J.; Chen, J. A review: the pharmacology of isoliquiritigenin. Phytother. Res., 2015, 29(7), 969-977. doi: 10.1002/ptr.5348 PMID: 25907962
  29. Traboulsi, H.; Cloutier, A.; Boyapelly, K.; Bonin, M.A.; Marsault, É.; Cantin, A.M.; Richter, M.V. The flavonoid isoliquiritigenin reduces lung inflammation and mouse morbidity during influenza virus infection. Antimicrob. Agents Chemother., 2015, 59(10), 6317-6327. doi: 10.1128/AAC.01098-15 PMID: 26248373
  30. Boyapelly, K.; Bonin, M.A.; Traboulsi, H.; Cloutier, A.; Phaneuf, S.C.; Fortin, D.; Cantin, A.M.; Richter, M.V.; Marsault, E. Synthesis and characterization of a phosphate prodrug of isoliquiritigenin. J. Nat. Prod., 2017, 80(4), 879-886. doi: 10.1021/acs.jnatprod.6b00600 PMID: 28252963
  31. Wu, C.; Yan, J.; Li, W. Acacetin as a potential protective compound against cardiovascular diseases. Evid.-. Based Complement. Altern. Med., 2022, 2022, 6265198. doi: 10.1155/2022/6265198
  32. Liu, H.; Wang, Y.J.; Yang, L.; Zhou, M.; Jin, M.W.; Xiao, G.S.; Wang, Y.; Sun, H.Y.; Li, G.R. Synthesis of a highly water-soluble acacetin prodrug for treating experimental atrial fibrillation in beagle dogs. Sci. Rep., 2016, 6(1), 25743. doi: 10.1038/srep25743 PMID: 27160397
  33. Zhu, C.; Wang, R.; Zheng, W.; Chen, D.; Yue, X.; Cao, Y.; Qin, W.; Sun, H.; Wang, Y.; Liu, Z.; Li, B.; Du, J.; Bu, X.; Zhou, B. Synthesis and evaluation of anticancer activity of BOC26P, an ortho-aryl chalcone sodium phosphate as water-soluble prodrugs in vitro and in vivo. Biomed. Pharmacother., 2017, 96, 551-562. doi: 10.1016/j.biopha.2017.10.006 PMID: 29032339
  34. Sudhan, D.R.; Siemann, D.W. Cathepsin L targeting in cancer treatment. Pharmacol. Ther., 2015, 155, 105-116. doi: 10.1016/j.pharmthera.2015.08.007 PMID: 26299995
  35. Sudhan, D.R.; Siemann, D.W. Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells. Clin. Exp. Metastasis, 2013, 30(7), 891-902. doi: 10.1007/s10585-013-9590-9 PMID: 23748470
  36. Parker, E.N.; Song, J.; Kishore Kumar, G.D.; Odutola, S.O.; Chavarria, G.E.; Charlton-Sevcik, A.K.; Strecker, T.E.; Barnes, A.L.; Sudhan, D.R.; Wittenborn, T.R.; Siemann, D.W.; Horsman, M.R.; Chaplin, D.J.; Trawick, M.L.; Pinney, K.G. Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. Bioorg. Med. Chem., 2015, 23(21), 6974-6992. doi: 10.1016/j.bmc.2015.09.036 PMID: 26462052
  37. Parker, E.N.; Odutola, S.O.; Wang, Y.; Strecker, T.E.; Mukherjee, R.; Shi, Z.; Chaplin, D.J.; Trawick, M.L.; Pinney, K.G. Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L. Bioorg. Med. Chem. Lett., 2017, 27(5), 1304-1310. doi: 10.1016/j.bmcl.2016.12.039 PMID: 28117205
  38. Liu, Q. Triptolide and its expanding multiple pharmacological functions. Int. Immunopharmacol., 2011, 11(3), 377-383. doi: 10.1016/j.intimp.2011.01.012 PMID: 21255694
  39. Patil, S.; Lis, L.G.; Schumacher, R.J.; Norris, B.J.; Morgan, M.L.; Cuellar, R.A.D.; Blazar, B.R.; Suryanarayanan, R.; Gurvich, V.J.; Georg, G.I. Phosphonooxymethyl prodrug of triptolide: Synthesis, physicochemical characterization, and efficacy in human colon adenocarcinoma and ovarian cancer xenografts. J. Med. Chem., 2015, 58(23), 9334-9344. doi: 10.1021/acs.jmedchem.5b01329 PMID: 26596892
  40. Dulac, M.; Sassi, A.; Nagarathinan, C.; Christen, M.O.; Dansette, P.M.; Mansuy, D.; Boucher, J.L. Metabolism of anethole dithiolethione by rat and human liver microsomes: formation of various products deriving from its O-demethylation and S-oxidation. Involvement of cytochromes P450 and flavin monooxygenases in these pathways. Drug Metab. Dispos., 2018, 46(10), 1390-1395. doi: 10.1124/dmd.118.082545 PMID: 30018103
  41. Chen, P.; Luo, Y.; Hai, L.; Qian, S.; Wu, Y. Design, synthesis, and pharmacological evaluation of the aqueous prodrugs of desmethyl anethole trithione with hepatoprotective activity. Eur. J. Med. Chem., 2010, 45(7), 3005-3010. doi: 10.1016/j.ejmech.2010.03.029 PMID: 20392547
  42. Huang, S.; Dong, R.; Xu, G.; Liu, J.; Gao, X.; Yu, S.; Qie, P.; Gou, G.; Hu, M.; Wang, Y.; Peng, J.; Guang, B.; Xu, Y.; Yang, T. Synthesis, characterization, and in vivo evaluation of desmethyl anethole trithione phosphate prodrug for ameliorating cerebral ischemia-reperfusion injury in rats. ACS Omega, 2020, 5(9), 4595-4602. doi: 10.1021/acsomega.9b04129 PMID: 32175506
  43. Zocchi, L.; Wu, S.C.; Wu, J.; Hayama, K.L.; Benavente, C.A. The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells. Oncotarget, 2018, 9(34), 23505-23518. doi: 10.18632/oncotarget.25239 PMID: 29805751
  44. Siddiqui-jain Adam. B.D.J. Alvocidib prodrugs having increased bioavailability. Patent no. WO2016187316, 2016.
  45. George, B.; Richards, D.A.; Edenfield, W.J.; Warner, S.L.; Mouritsen, L.; Bishop, R.; Anthony, S.P.; Bearss, D.; Vogelzang, N.J.; Whatcott, C. A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors. J. Clin. Oncol., 2020, 38(15), 3611. doi: 10.1200/JCO.2020.38.15_suppl.3611
  46. Buckley, A.M.; Dunne, M.R.; Lynam-Lennon, N.; Kennedy, S.A.; Cannon, A.; Reynolds, A.L.; Maher, S.G.; Reynolds, J.V.; Kennedy, B.N.; O’Sullivan, J. Pyrazinib (P3), (E)-2-(2-Pyrazin-2-yl-vinyl)-phenol, a small molecule pyrazine compound enhances radiosensitivity in oesophageal adenocarcinoma. Cancer Lett., 2019, 447, 115-129. doi: 10.1016/j.canlet.2019.01.009 PMID: 30664962
  47. McLoughlin, E.; Valupadasu, N.; O’Boyle, N.M. A phosphate prodrug of pyrazinib: Improved solubility and antiproliferative activity. 7th International Electronic Conference on Medicinal Chemistry Session Fighting Cancers, 1-30 November 2021MDPI: Basel, Switzerland.
  48. Prasad, R.; Katiyar, S.K. Honokiol, an active compound of magnolia plant, inhibits growth, and progression of cancers of different organs. Adv. Exp. Med. Biol., 2016, 928, 245-265. doi: 10.1007/978-3-319-41334-1_11
  49. Arora, S.; Singh, S.; Piazza, G.A.; Contreras, C.M.; Panyam, J.; Singh, A.P. Honokiol: a novel natural agent for cancer prevention and therapy. Curr. Mol. Med., 2012, 12(10), 1244-1252. doi: 10.2174/156652412803833508 PMID: 22834827
  50. Xu, G.; Dong, R.; Liu, J.; Zhao, L.; Zeng, Y.; Xiao, X.; An, J.; Huang, S.; Zhong, Y.; Guang, B. Synthesis, characterization and in vivo evaluation of honokiol bisphosphate prodrugs protects against rats’ brain ischemia-reperfusion injury. Asian J. Pharmaceut. Sci., 2019, 14(6), 640-648.
  51. Talley, A.K.; Thurston, A.; Moore, G.; Gupta, V.K.; Satterfield, M.; Manyak, E.; Stokes, S.; Dane, A.; Melnick, D. First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections. Antimicrob. Agents Chemother., 2021, 65(11), e01208-21. doi: 10.1128/AAC.01208-21 PMID: 34491803
  52. Stokes, S.S.; Vemula, R.; Pucci, M.J. Advancement of GyrB inhibitors for treatment of infections caused by Mycobacterium tuberculosis and non-tuberculous mycobacteria. ACS Infect. Dis., 2020, 6(6), 1323-1331. doi: 10.1021/acsinfecdis.0c00025 PMID: 32183511
  53. Butler, M.S.; Gigante, V.; Sati, H.; Paulin, S.; Al-Sulaiman, L.; Rex, J.H.; Fernandes, P.; Arias, C.A.; Paul, M.; Thwaites, G.E.; Czaplewski, L.; Alm, R.A.; Lienhardt, C.; Spigelman, M.; Silver, L.L.; Ohmagari, N.; Kozlov, R.; Harbarth, S.; Beyer, P. Analysis of the clinical pipeline of treatments for drug-resistant bacterial infections: despite progress, more action is needed. Antimicrob. Agents Chemother., 2022, 66(3), e01991-21. doi: 10.1128/aac.01991-21 PMID: 35007139
  54. Kumar, A.; Karkara, B.B.; Panda, G. Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches. Chem. Biol. Drug Des., 2021, 98(5), 787-827. doi: 10.1111/cbdd.13934 PMID: 34397161
  55. Spero Therapeutics. Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720. Available from: https://www.globenewswire.com/en/news-release/2022/01/04/2360795/0/en/Spero-Therapeutics-Announces-Lifting-of-FDA-Clinical-Trial-Hold-on-SPR720.html
  56. Tozer, G.M.; Kanthou, C.; Parkins, C.S.; Hill, S.A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol., 2002, 83(1), 21-38. doi: 10.1046/j.1365-2613.2002.00211.x PMID: 12059907
  57. Garon, E.B.; Neidhart, J.D.; Gabrail, N.Y.; de Oliveira, M.R.; Balkissoon, J.; Kabbinavar, F. A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. OncoTargets Ther., 2016, 9, 7275-7283. doi: 10.2147/OTT.S109186 PMID: 27942221
  58. Tron, G.C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A.A. Medicinal chemistry of combretastatin A4: present and future directions. J. Med. Chem., 2006, 49(11), 3033-3044. doi: 10.1021/jm0512903 PMID: 16722619
  59. Zhang, C.; Zhang, X.; Wang, G.; Peng, Y.; Zhang, X.; Wu, H.; Yu, B.; Sun, J. Preclinical pharmacokinetics of C118P, a novel prodrug of microtubules inhibitor and its metabolite C118 in mice, rats, and dogs. Molecules, 2018, 23(11), 2883. doi: 10.3390/molecules23112883 PMID: 30400617
  60. Deeks, E.D. Venetoclax: first global approval. Drugs, 2016, 76(9), 979-987. doi: 10.1007/s40265-016-0596-x PMID: 27260335
  61. Tresckow, J.V.; Eichhorst, B.; Bahlo, J.; Hallek, M. The treatment of chronic lymphatic leukemia. Dtsch. Arztebl. Int., 2019, 116(4), 41-46. PMID: 30855005
  62. Salem, A.H.; Tao, Z.F.; Bueno, O.F.; Chen, J.; Chen, S.; Edalji, R.; Elmore, S.W.; Fournier, K.M.; Harper, K.C.; Hong, R.; Jenkins, G.J.; Ji, J.; Judge, R.A.; Kalvass, J.C.; Klix, R.C.; Ku, Y.Y.; Leverson, J.D.; Marks, R.A.; Marsh, K.C.; Menon, R.M.; Park, C.H.; Phillips, D.C.; Pu, Y.M.; Rosenberg, S.H.; Sanzgiri, Y.D.; Sheikh, A.Y.; Shi, Y.; Stolarik, D.; Suleiman, A.A.; Wang, X.; Zhang, G.G.Z.; Catron, N.D.; Souers, A.J. Expanding the repertoire for "Large Small Molecules": Prodrug ABBV-167 efficiently converts to venetoclax with reduced food effect in healthy volunteers. Mol. Cancer Ther., 2021, 20(6), 999-1008. doi: 10.1158/1535-7163.MCT-21-0077 PMID: 33785651
  63. Bristow, L.J.; Gulia, J.; Weed, M.R.; Srikumar, B.N.; Li, Y.W.; Graef, J.D.; Naidu, P.S.; Sanmathi, C.; Aher, J.; Bastia, T.; Paschapur, M.; Kalidindi, N.; Kumar, K.V.; Molski, T.; Pieschl, R.; Fernandes, A.; Brown, J.M.; Sivarao, D.V.; Newberry, K.; Bookbinder, M.; Polino, J.; Keavy, D.; Newton, A.; Shields, E.; Simmermacher, J.; Kempson, J.; Li, J.; Zhang, H.; Mathur, A.; Kallem, R.R.; Sinha, M.; Ramarao, M.; Vikramadithyan, R.K.; Thangathirupathy, S.; Warrier, J.; Islam, I.; Bronson, J.J.; Olson, R.E.; Macor, J.E.; Albright, C.F.; King, D.; Thompson, L.A.; Marcin, L.R.; Sinz, M. Preclinical characterization of (R)-3-((3S, 4S)-3-fluoro-4-(4-hydroxyphenyl) piperidin-1-yl)-1-(4-methylbenzyl) pyrrolidin-2-one (BMS-986169), a novel, intravenous, glutamate N-methyl-d-aspartate 2B receptor negative allosteric modulator with potential in major depressive disorder. J. Pharmacol. Exp. Ther., 2017, 363(3), 377-393. doi: 10.1124/jpet.117.242784 PMID: 28954811
  64. Marcin, L.R.; Warrier, J.; Thangathirupathy, S.; Shi, J.; Karageorge, G.N.; Pearce, B.C.; Ng, A.; Park, H.; Kempson, J.; Li, J.; Zhang, H.; Mathur, A.; Reddy, A.B.; Nagaraju, G.; Tonukunuru, G.; Gupta, G.V.R.K.M.; Kamble, M.; Mannoori, R.; Cheruku, S.; Jogi, S.; Gulia, J.; Bastia, T.; Sanmathi, C.; Aher, J.; Kallem, R.; Srikumar, B.N.; Vijaya, K.K.; Naidu, P.S.; Paschapur, M.; Kalidindi, N.; Vikramadithyan, R.; Ramarao, M.; Denton, R.; Molski, T.; Shields, E.; Subramanian, M.; Zhuo, X.; Nophsker, M.; Simmermacher, J.; Sinz, M.; Albright, C.; Bristow, L.J.; Islam, I.; Bronson, J.J.; Olson, R.E.; King, D.; Thompson, L.A.; Macor, J.E. BMS-986163, a negative allosteric modulator of GluN2B with potential utility in major depressive disorder. ACS Med. Chem. Lett., 2018, 9(5), 472-477. doi: 10.1021/acsmedchemlett.8b00080 PMID: 29795762
  65. de Vries, M.; Mohamed, A.S.; Prescott, R.A.; Valero-Jimenez, A.M.; Ivanova, A.H.; Schinlever, A.; Loose, P.; Ruggles, K.; Sergei, B.; Koralov, A.S. A comparative analysis of SARS-CoV-2 antivirals in human airway models 1 characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for 2 COVID-19. J. Virol., 2021, 95(10), e01819-20. doi: 10.1128/JVI.01819-20
  66. Boras, B.; Jones, R.M.; Anson, B.J.; Arenson, D.; Aschenbrenner, L.; Bakowski, M.A.; Beutler, N.; Binder, J.; Chen, E.; Eng, H.; Hammond, H.; Hammond, J.; Haupt, R.E.; Hoffman, R.; Kadar, E.P.; Kania, R.; Kimoto, E.; Kirkpatrick, M.G.; Lanyon, L.; Lendy, E.K.; Lillis, J.R.; Logue, J.; Luthra, S.A.; Ma, C.; Mason, S.W.; McGrath, M.E.; Noell, S.; Obach, R.S.; O’ Brien, M.N.; O’Connor, R.; Ogilvie, K.; Owen, D.; Pettersson, M.; Reese, M.R.; Rogers, T.F.; Rosales, R.; Rossulek, M.I.; Sathish, J.G.; Shirai, N.; Steppan, C.; Ticehurst, M.; Updyke, L.W.; Weston, S.; Zhu, Y.; White, K.M.; García-Sastre, A.; Wang, J.; Chatterjee, A.K.; Mesecar, A.D.; Frieman, M.B.; Anderson, A.S.; Allerton, C. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat. Commun., 2021, 12(1), 6055. doi: 10.1038/s41467-021-26239-2 PMID: 34663813
  67. Zhu, T.; Pawlak, S.; Toussi, S.S.; Hackman, F.; Thompson, K.; Song, W.; Salageanu, J.; Winter, E.; Shi, H.; Winton, J.; Binks, M. Safety, tolerability, and pharmacokinetics of intravenous doses of PF-07304814, a phosphate prodrug protease inhibitor for the treatment of SARS-CoV-2, in healthy adult participants. Clin. Pharmacol. Drug Dev., 2022, 11(12), 1382-1393. doi: 10.1002/cpdd.1174 PMID: 36285536

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Bentham Science Publishers